about
AAV-Mediated Gene Supplementation Therapy in Achromatopsia Type 2: Preclinical Data on Therapeutic Time Window and Long-Term EffectsWhole Genome Sequencing Revealed Mutations in Two Independent Genes as the Underlying Cause of Retinal Degeneration in an Ashkenazi Jewish Pedigree.Incidence of Atrophic Lesions in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 5.Gene therapy for achromatopsia.Applications of CRISPR/Cas9 in retinal degenerative diseasesAcupuncture benefits for Flammer syndrome in individuals with inherited diseases of the retinaNext-generation sequencing reveals the mutational landscape of clinically diagnosed Usher syndrome: copy number variations, phenocopies, a predominant target for translational read-through, and PEX26 mutated in Heimler syndrome.Long-term photoreceptor rescue in two rodent models of retinitis pigmentosa by adeno-associated virus delivery of Stanniocalcin-1.Design and Development of AAV-based Gene Supplementation Therapies for Achromatopsia and Retinitis Pigmentosa.Adaptive optics imaging of inherited retinal diseases.Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9).Molecular Anatomy of the Developing Human Retina.And Then There Was Light: Perspectives of Optogenetics for Deep Brain Stimulation and Neuromodulation.Channelrhodopsin reveals its dark secrets.Structural insights into ion conduction by channelrhodopsin 2.A live cell assay of GPCR coupling allows identification of optogenetic tools for controlling Go and Gi signaling.Toward an elucidation of the molecular genetics of inherited retinal degenerations.Hyperpolarization by activation of halorhodopsin results in enhanced synaptic transmission: Neuromuscular junction and CNS circuit.An Atomistic Model of a Precursor State of Light-Induced Channel Opening of ChannelrhodopsinVisual Acuity Change Over 24 Months and Its Association With Foveal Phenotype and Genotype in Individuals With Stargardt Disease: ProgStar Study Report No. 10Probing Synaptic Transmission and Behavior in with Optogenetics: A Laboratory Exercise
P2860
Q36396453-E30F74B3-02C1-4568-AA3E-51C581039968Q38610400-57162744-6168-44B9-B2DE-CD342FB57082Q38679198-69A17BDC-B274-44F0-AF6B-A50494E854E0Q39016569-C7DD185D-F93A-4C9A-A29B-0CEDF3C16234Q39306038-E5255A1F-87F9-4DC6-824F-4882971C633FQ41030893-34446333-3D12-406F-9B01-1E0978BF4DE7Q41696457-959FBE11-EC7E-45AD-9C04-D948A10FF4C5Q41925201-8D410C23-D86F-421F-80A2-B69E311B2B9EQ45875179-E28BB929-B4E7-4DE6-9807-70C68D07EA1BQ46250842-CE602985-FE67-42DE-8FEA-478D876BD030Q46455405-A5A58A50-58A6-4676-B198-093D8735EF43Q46485872-121BACB6-F707-45A2-91B7-5C09586CDBF0Q47300209-D0D4C87E-E55D-489C-918C-FA08365970BDQ47369744-7A34ED22-6CF0-445F-A15C-F3764487396AQ47783696-6EBA0D1B-9697-4163-84FB-92552EA2220AQ49196113-076F621D-FEF5-42D4-BD37-B50825D63B7EQ50998111-6FD4B43F-9F68-4A5A-AEE4-4AA16EEC7878Q55717814-DB616C13-2AE6-4B6F-9819-AEF72BE838AFQ57044261-B48A8E44-4A9A-47A6-850E-676D60247C8CQ57173001-9B3CBE89-EFBA-4315-B8B4-2FFAEDE2BFB5Q58737290-810EE474-F865-4AA6-8D31-12A4FA3D7822
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Emerging therapies for inherited retinal degeneration.
@en
Emerging therapies for inherited retinal degeneration.
@nl
type
label
Emerging therapies for inherited retinal degeneration.
@en
Emerging therapies for inherited retinal degeneration.
@nl
prefLabel
Emerging therapies for inherited retinal degeneration.
@en
Emerging therapies for inherited retinal degeneration.
@nl
P2093
P2860
P50
P1476
Emerging therapies for inherited retinal degeneration.
@en
P2093
Botond Roska
Hendrik P N Scholl
Mandeep S Singh
Rupert W Strauss
P2860
P304
P356
10.1126/SCITRANSLMED.AAF2838
P407
P577
2016-12-01T00:00:00Z